Apollomics Presents Data from Phase 2 Clinical Trials of Lung Cancer Medication
By Thomas S. Green Apollomics Inc. (Nasdaq: APLM) said it saw strong results from two clinical trials for Vebreltinib, designed to target non-small cell lung...
By Thomas S. Green Apollomics Inc. (Nasdaq: APLM) said it saw strong results from two clinical trials for Vebreltinib, designed to target non-small cell lung...